CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELLIN 肿瘤细胞治疗研究

← 返回

难治/复发性结内和结外弥漫大 B 细胞淋巴瘤在 CAR-T 细胞治疗时代的预后差异

英文原题：Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.

查看英文原题

Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.

PubMed 2022/06/02（内容时间） Clin Chim Acta Q1 · IF 4.1（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

技术：CAR-T技术：造血干细胞弥漫大B细胞淋巴瘤淋巴瘤地区：中国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

在接受 CAR-T 治疗的患者中，R/R EN-DLBCL 的临床结局比 R/R N-DLBCL 更差，而 ASCT + CAR-T 治疗是 R/R EN-DLBCL 患者一种有前景的替代治疗选择。

研究思路结论见上方概要

背景

结外受累被认为是弥漫大B细胞淋巴瘤（DLBCL）的不良预后因素。然而，在CAR-T 细胞治疗时代，难治/复发（R/R）结内和结外DLBCL患者的预后差异仍不清楚。

方法

本研究纳入18例R/R结内DLBCL（R/R N-DLBCL）和19例R/R结外DLBCL（R/R EN-DLBCL），比较临床结局。

结果

中位随访时间为13（范围，1-47）个月，淋巴结和结外患者之间的1年无进展生存期（PFS；83.3% vs. 42.1%，P = 0.008）和1年总生存期（OS；94.4% vs. 63.2%，P = 0.020）存在显著差异。在多变量Cox回归分析中，与R/R N-DLBCL相比，R/R EN-DLBCL与更差的PFS（风险比[HR] = 4.263，P = 0.018）和OS（HR = 9.589，P = 0.034）相关。此外，与单独CAR-T 治疗相比，自体造血干细胞移植（ASCT）联合CAR-T 治疗（ASCT + CAR-T）与更好的PFS相关（HR = 0.164，P = 0.003）。

展开英文摘要原文
BACKGROUND

Extranodal involvement is recognized as a poor prognostic factor for diffuse large B-cell lymphoma (DLBCL). However, the prognostic differences of patients with refractory/relapsed (R/R) nodal and extranodal DLBCL in the chimeric antigen receptor T cell (CART) therapy era are still unclear.

MATERIALS AND METHODS

In this study, 18 R/R nodal DLBCL (R/R N-DLBCL) and 19 R/R extranodal DLBCL (R/R EN-DLBCL) were enrolled to compare clinical outcomes.

RESULTS

The median follow-up time was 13 (range, 1-47) months and one-year progression-free survival (PFS; 83.3% vs. 42.1%, P = 0.008) and one-year overall survival (OS; 94.4% vs. 63.2%, P = 0.020) were significantly different between nodal and extranodal patients. In the multivariable Cox regression analysis, R/R EN-DLBCL was associated with worse PFS (hazard ratio [HR] = 4.263, P = 0.018) and OS (HR = 9.589, P = 0.034) compared to R/R N-DLBCL. Additionally, autologous hematopoietic stem cell transplantation (ASCT) combined with CART therapy (ASCT + CART) was correlated with better PFS (HR = 0.164, P = 0.003) compared to CART treatment alone.

CONCLUSIONS

The clinical outcomes of R/R EN-DLBCL were worse than R/R N-DLBCL in patients receiving CART therapy and ASCT + CART therapy is a promising alternative treatment for patients with R/R EN-DLBCL.

论文信息

作者
Song Z、Xu L、Tang G、Gao L、Wang L、Ni X、Chen L、Chen J
第一作者单位
Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.China
通讯作者单位
Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Electronic address: yang060124@126.com.China
期刊
Clinica chimica acta; international journal of clinical chemistry2022 Jul 1
原文标识
PubMed 35660013　·　DOI 10.1016/j.cca.2022.05.018

在 PubMed 查看 → 出版商原文（DOI） 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →